<DOC>
	<DOCNO>NCT01780714</DOCNO>
	<brief_summary>The goal exploratory study evaluate effect candidate modify risk tobacco product ( MRTP ) , THS 2.1 , select biomarkers exposure harmful potentially harmful smoke constituent ( HPHCs ) , compare conventional cigarette ( CC ) . The subjective effect ( urge smoke withdrawal symptom ) relate use product explore . Initial information safety biological effect use THS 2.1 collect . Human Smoking Topography ( HST ) explore .</brief_summary>
	<brief_title>Exploratory THS 2.1 Biomarkers Exposure Study</brief_title>
	<detailed_description>This study intend evaluate level select biomarkers exposure select HPHC cytochrome P450 1A2 ( CYP1A2 ) enzymatic activity , compare smoker continue smoke CC ad libitum , 5 day ad libitum use . Additional parameter explore , : cytochrome P450 2A6 ( CYP2A6 ) enzymatic activity , nicotine pharmacokinetics , product evaluation safety , marker platelet function , HST . After screen , subject admit clinic 9 day , include Day Admission , 2 day baseline subject continue smoke usual CC 5-day exposure randomization . After leave clinic Day Discharge , subject follow safety period 7 day . All subject receive smoke cessation advice screening , Day Admission Day Discharge . This clinical study conduct compliance International Conference Harmonisation technical requirement registration pharmaceutical human use ( ICH Good Clinical Practice ) , Declaration Helsinki amend 2008 , applicable regulatory requirement .</detailed_description>
	<criteria>Subject sign informed consent form commencement study procedures Healthy Caucasian age 23 65 year Subject current smoker least 3 year ( base selfreporting biochemically verify ) , , last 4 week , smoke least 10 commercially available nonmentholated CC per day , plan make quit attempt within next 3 month Main As per Investigator judgment , subject participate study reason ( e.g . medical , psychiatric and/or social reason ) The subject medical condition require smoke cessation , clinically relevant disease / condition could interfere study participation and/or study result The subject participate clinical study within 3 month prior Screening Visit Pregnant lactate woman , woman childbearing potential , absence / refusal use acceptable method effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>smoking</keyword>
	<keyword>cigarette</keyword>
	<keyword>exposure</keyword>
	<keyword>biomarker</keyword>
	<keyword>human smoking topography ( HST )</keyword>
	<keyword>modify risk tobacco product ( MRTP )</keyword>
	<keyword>THS 2.1</keyword>
</DOC>